1
|
Babbe H, Sundberg TB, Tichenor M, Seierstad M, Bacani G, Berstler J, Chai W, Chang L, Chung DM, Coe K, Collins B, Finley M, Guletsky A, Lemke CT, Mak PA, Mathur A, Mercado-Marin EV, Metkar S, Raymond DD, Rives ML, Rizzolio M, Shaffer PL, Smith R, Smith J, Steele R, Steffens H, Suarez J, Tian G, Majewski N, Volak LP, Wei J, Desai PT, Ong LL, Koudriakova T, Goldberg SD, Hirst G, Kaushik VK, Ort T, Seth N, Graham DB, Plevy S, Venable JD, Xavier RJ, Towne JE. Identification of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation. Proc Natl Acad Sci U S A 2024; 121:e2307086120. [PMID: 38147543 PMCID: PMC10769863 DOI: 10.1073/pnas.2307086120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 11/07/2023] [Indexed: 12/28/2023] Open
Abstract
The salt-inducible kinases (SIK) 1-3 are key regulators of pro- versus anti-inflammatory cytokine responses during innate immune activation. The lack of highly SIK-family or SIK isoform-selective inhibitors suitable for repeat, oral dosing has limited the study of the optimal SIK isoform selectivity profile for suppressing inflammation in vivo. To overcome this challenge, we devised a structure-based design strategy for developing potent SIK inhibitors that are highly selective against other kinases by engaging two differentiating features of the SIK catalytic site. This effort resulted in SIK1/2-selective probes that inhibit key intracellular proximal signaling events including reducing phosphorylation of the SIK substrate cAMP response element binding protein (CREB) regulated transcription coactivator 3 (CRTC3) as detected with an internally generated phospho-Ser329-CRTC3-specific antibody. These inhibitors also suppress production of pro-inflammatory cytokines while inducing anti-inflammatory interleukin-10 in activated human and murine myeloid cells and in mice following a lipopolysaccharide challenge. Oral dosing of these compounds ameliorates disease in a murine colitis model. These findings define an approach to generate highly selective SIK1/2 inhibitors and establish that targeting these isoforms may be a useful strategy to suppress pathological inflammation.
Collapse
Affiliation(s)
- Holger Babbe
- Janssen Research and Development, LLC., Spring House, PA19477
| | - Thomas B. Sundberg
- Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA02142
| | - Mark Tichenor
- Janssen Research and Development, LLC., San Diego, CA92121
| | - Mark Seierstad
- Janssen Research and Development, LLC., San Diego, CA92121
| | - Genesis Bacani
- Janssen Research and Development, LLC., San Diego, CA92121
| | - James Berstler
- Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA02142
| | - Wenying Chai
- Janssen Research and Development, LLC., San Diego, CA92121
| | - Leon Chang
- Janssen Research and Development, LLC., San Diego, CA92121
| | | | - Kevin Coe
- Janssen Research and Development, LLC., San Diego, CA92121
| | | | - Michael Finley
- Janssen Research and Development, LLC., Spring House, PA19477
| | - Alexander Guletsky
- Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA02142
| | - Christopher T. Lemke
- Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA02142
| | - Puiying A. Mak
- Janssen Research and Development, LLC., San Diego, CA92121
| | - Ashok Mathur
- Janssen Research and Development, LLC., Spring House, PA19477
| | | | - Shailesh Metkar
- Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA02142
| | - Donald D. Raymond
- Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA02142
| | | | | | - Paul L. Shaffer
- Janssen Research and Development, LLC., Spring House, PA19477
| | - Russell Smith
- Janssen Research and Development, LLC., San Diego, CA92121
| | | | - Ruth Steele
- Janssen Research and Development, LLC., Spring House, PA19477
| | | | - Javier Suarez
- Janssen Research and Development, LLC., Spring House, PA19477
| | - Gaochao Tian
- Janssen Research and Development, LLC., Spring House, PA19477
| | - Nathan Majewski
- Janssen Research and Development, LLC., Spring House, PA19477
| | | | - Jianmei Wei
- Janssen Research and Development, LLC., San Diego, CA92121
| | - Prerak T. Desai
- Janssen Research and Development, LLC., Spring House, PA19477
| | - Luvena L. Ong
- Janssen Research and Development, LLC., Spring House, PA19477
| | | | | | - Gavin Hirst
- Janssen Research and Development, LLC., San Diego, CA92121
| | - Virendar K. Kaushik
- Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA02142
| | - Tatiana Ort
- Janssen Research and Development, LLC., Spring House, PA19477
| | - Nilufer Seth
- Janssen Research and Development, LLC., Spring House, PA19477
| | - Daniel B. Graham
- Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA02114
- Department of Molecular Biology, Massachusetts General Hospital, Boston, MA02114
- Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA02142
| | - Scott Plevy
- Janssen Research and Development, LLC., Spring House, PA19477
| | | | - Ramnik J. Xavier
- Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA02114
- Department of Molecular Biology, Massachusetts General Hospital, Boston, MA02114
- Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA02142
| | | |
Collapse
|
2
|
Wang J, Nakafuku KM, Ziff J, Gelin CF, Gholami H, Thompson AA, Karpowich NK, Limon L, Coate HR, Damm-Ganamet KL, Shih AY, Grant JC, Côte M, Mak PA, Pascual HA, Rives ML, Edwards JP, Venable JD, Venkatesan H, Shi Z, Allen SJ, Sharma S, Kung PP, Shireman BT. Development of small molecule inhibitors of natural killer group 2D receptor (NKG2D). Bioorg Med Chem Lett 2023; 96:129492. [PMID: 37778428 DOI: 10.1016/j.bmcl.2023.129492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 09/25/2023] [Accepted: 09/28/2023] [Indexed: 10/03/2023]
Abstract
Natural killer group 2D (NKG2D) is a homodimeric activating immunoreceptor whose function is to detect and eliminate compromised cells upon binding to the NKG2D ligands (NKG2DL) major histocompatibility complex (MHC) molecules class I-related chain A (MICA) and B (MICB) and UL16 binding proteins (ULBP1-6). While typically present at low levels in healthy cells and tissue, NKG2DL expression can be induced by viral infection, cellular stress or transformation. Aberrant activity along the NKG2D/NKG2DL axis has been associated with autoimmune diseases due to the increased expression of NKG2D ligands in human disease tissue, making NKG2D inhibitors an attractive target for immunomodulation. Herein we describe the discovery and optimization of small molecule PPI (protein-protein interaction) inhibitors of NKG2D/NKG2DL. Rapid SAR was guided by structure-based drug design and accomplished by iterative singleton and parallel medicinal chemistry synthesis. These efforts resulted in the identification of several potent analogs (14, 21, 30, 45) with functional activity and improved LLE.
Collapse
Affiliation(s)
- Jocelyn Wang
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States.
| | - Kohki M Nakafuku
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States.
| | - Jeannie Ziff
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Christine F Gelin
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Hadi Gholami
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Aaron A Thompson
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Nathan K Karpowich
- Janssen Research & Development L.L.C., 1400 McKean Rd., Spring House, PA 19477, United States
| | - Luis Limon
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Heather R Coate
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Kelly L Damm-Ganamet
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Amy Y Shih
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Joanna C Grant
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Marjorie Côte
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Puiying A Mak
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Heather A Pascual
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Marie-Laure Rives
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - James P Edwards
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Jennifer D Venable
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Hariharan Venkatesan
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Zhicai Shi
- Janssen Research & Development L.L.C., 1400 McKean Rd., Spring House, PA 19477, United States
| | - Samantha J Allen
- Janssen Research & Development L.L.C., 1400 McKean Rd., Spring House, PA 19477, United States
| | - Sujata Sharma
- Janssen Research & Development L.L.C., 1400 McKean Rd., Spring House, PA 19477, United States
| | - Pei-Pei Kung
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| | - Brock T Shireman
- Janssen Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, United States
| |
Collapse
|
3
|
Thompson AA, Harbut MB, Kung PP, Karpowich NK, Branson JD, Grant JC, Hagan D, Pascual HA, Bai G, Zavareh RB, Coate HR, Collins BC, Côte M, Gelin CF, Damm-Ganamet KL, Gholami H, Huff AR, Limon L, Lumb KJ, Mak PA, Nakafuku KM, Price EV, Shih AY, Tootoonchi M, Vellore NA, Wang J, Wei N, Ziff J, Berger SB, Edwards JP, Gardet A, Sun S, Towne JE, Venable JD, Shi Z, Venkatesan H, Rives ML, Sharma S, Shireman BT, Allen SJ. Identification of small-molecule protein-protein interaction inhibitors for NKG2D. Proc Natl Acad Sci U S A 2023; 120:e2216342120. [PMID: 37098070 PMCID: PMC10160951 DOI: 10.1073/pnas.2216342120] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2022] [Accepted: 03/10/2023] [Indexed: 04/26/2023] Open
Abstract
NKG2D (natural-killer group 2, member D) is a homodimeric transmembrane receptor that plays an important role in NK, γδ+, and CD8+ T cell-mediated immune responses to environmental stressors such as viral or bacterial infections and oxidative stress. However, aberrant NKG2D signaling has also been associated with chronic inflammatory and autoimmune diseases, and as such NKG2D is thought to be an attractive target for immune intervention. Here, we describe a comprehensive small-molecule hit identification strategy and two distinct series of protein-protein interaction inhibitors of NKG2D. Although the hits are chemically distinct, they share a unique allosteric mechanism of disrupting ligand binding by accessing a cryptic pocket and causing the two monomers of the NKG2D dimer to open apart and twist relative to one another. Leveraging a suite of biochemical and cell-based assays coupled with structure-based drug design, we established tractable structure-activity relationships with one of the chemical series and successfully improved both the potency and physicochemical properties. Together, we demonstrate that it is possible, albeit challenging, to disrupt the interaction between NKG2D and multiple protein ligands with a single molecule through allosteric modulation of the NKG2D receptor dimer/ligand interface.
Collapse
Affiliation(s)
- Aaron A. Thompson
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Michael B. Harbut
- Therapeutics Discovery, Janssen Research & Development, Lower Gwynedd Township, PA19002
| | - Pei-Pei Kung
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Nathan K. Karpowich
- Therapeutics Discovery, Janssen Research & Development, Lower Gwynedd Township, PA19002
| | - Jeffrey D. Branson
- Therapeutics Discovery, Janssen Research & Development, Lower Gwynedd Township, PA19002
| | - Joanna C. Grant
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Deborah Hagan
- Therapeutics Discovery, Janssen Research & Development, Lower Gwynedd Township, PA19002
| | - Heather A. Pascual
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Guoyun Bai
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | | | - Heather R. Coate
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Bernard C. Collins
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Marjorie Côte
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Christine F. Gelin
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | | | - Hadi Gholami
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Adam R. Huff
- Therapeutics Discovery, Janssen Research & Development, Lower Gwynedd Township, PA19002
| | - Luis Limon
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Kevin J. Lumb
- Therapeutics Discovery, Janssen Research & Development, Lower Gwynedd Township, PA19002
| | - Puiying A. Mak
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Kohki M. Nakafuku
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Edmund V. Price
- Therapeutics Discovery, Janssen Research & Development, Lower Gwynedd Township, PA19002
| | - Amy Y. Shih
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Mandana Tootoonchi
- Discovery Immunology, Janssen Research & Development, San Diego, CA92121
| | - Nadeem A. Vellore
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Jocelyn Wang
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Na Wei
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Jeannie Ziff
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Scott B. Berger
- Discovery Immunology, Janssen Research & Development, Lower Gwynedd Township, PA19002
| | - James P. Edwards
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Agnès Gardet
- Discovery Immunology, Janssen Research & Development, San Diego, CA92121
| | - Siquan Sun
- Discovery Immunology, Janssen Research & Development, San Diego, CA92121
| | - Jennifer E. Towne
- Discovery Immunology, Janssen Research & Development, San Diego, CA92121
| | | | - Zhicai Shi
- Therapeutics Discovery, Janssen Research & Development, Lower Gwynedd Township, PA19002
| | | | - Marie-Laure Rives
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Sujata Sharma
- Therapeutics Discovery, Janssen Research & Development, Lower Gwynedd Township, PA19002
| | - Brock T. Shireman
- Therapeutics Discovery, Janssen Research & Development, San Diego, CA92121
| | - Samantha J. Allen
- Therapeutics Discovery, Janssen Research & Development, Lower Gwynedd Township, PA19002
| |
Collapse
|
4
|
Tichenor MS, Wiener JJM, Rao NL, Bacani GM, Wei J, Pooley Deckhut C, Barbay JK, Kreutter KD, Chang L, Clancy KW, Murrey HE, Wang W, Ahn K, Huber M, Rex E, Coe KJ, Wu J, Rui H, Sepassi K, Gaudiano M, Bekkers M, Cornelissen I, Packman K, Seierstad M, Xiouras C, Bembenek SD, Alexander R, Milligan C, Balasubramanian S, Lebsack AD, Venable JD, Philippar U, Edwards JP, Hirst G. Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. J Med Chem 2022; 65:14326-14336. [DOI: 10.1021/acs.jmedchem.2c01026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Mark S. Tichenor
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - John J. M. Wiener
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Navin L. Rao
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Genesis M. Bacani
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Jianmei Wei
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Charlotte Pooley Deckhut
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - J. Kent Barbay
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Kevin D. Kreutter
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Leon Chang
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Kathleen W. Clancy
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Heather E. Murrey
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Weixue Wang
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Kay Ahn
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Michael Huber
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Elizabeth Rex
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Kevin J. Coe
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Jiejun Wu
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Haopeng Rui
- Janssen Research & Development, 4560 Jinke Road, Pudong New Area, Shanghai 201319, P. R. China
| | - Kia Sepassi
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Marcello Gaudiano
- Janssen Research & Development, Turnhoutseweg 30, B-2340 Beerse, Belgium
| | - Mariette Bekkers
- Janssen Research & Development, Turnhoutseweg 30, B-2340 Beerse, Belgium
| | - Ivo Cornelissen
- Janssen Research & Development, Turnhoutseweg 30, B-2340 Beerse, Belgium
| | - Kathryn Packman
- Janssen Research & Development, Turnhoutseweg 30, B-2340 Beerse, Belgium
| | - Mark Seierstad
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Christos Xiouras
- Janssen Research & Development, Turnhoutseweg 30, B-2340 Beerse, Belgium
| | - Scott D. Bembenek
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Richard Alexander
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Cynthia Milligan
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Sriram Balasubramanian
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Alec D. Lebsack
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Jennifer D. Venable
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Ulrike Philippar
- Janssen Research & Development, Turnhoutseweg 30, B-2340 Beerse, Belgium
| | - James P. Edwards
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Gavin Hirst
- Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| |
Collapse
|
5
|
Hendrick CE, Jorgensen JR, Chaudhry C, Strambeanu II, Brazeau JF, Schiffer J, Shi Z, Venable JD, Wolkenberg SE. Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation. ACS Med Chem Lett 2022; 13:1182-1190. [PMID: 35859867 PMCID: PMC9290060 DOI: 10.1021/acsmedchemlett.2c00124] [Citation(s) in RCA: 27] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Affiliation(s)
- Charles E. Hendrick
- Discovery Chemistry, Therapeutics Discovery, Janssen Research & Development, LLC,Welsh & McKean Roads, Spring House, Pennsylvania 19477, United States
| | - Jeff R. Jorgensen
- Discovery Technology and Molecular Pharmacology, Therapeutics Discovery, Janssen Research & Development, LLC, Welsh & McKean Roads, Spring House, Pennsylvania 19477, United States
| | - Charu Chaudhry
- Discovery Technology and Molecular Pharmacology, Therapeutics Discovery, Janssen Research & Development, LLC, Welsh & McKean Roads, Spring House, Pennsylvania 19477, United States
| | - Iulia I. Strambeanu
- Discovery Chemistry, Therapeutics Discovery, Janssen Research & Development, LLC,Welsh & McKean Roads, Spring House, Pennsylvania 19477, United States
| | - Jean-Francois Brazeau
- Discovery Chemistry, Therapeutics Discovery, Janssen Research & Development, LLC, 3210 Merryfield Row, La Jolla, California 92121, United States
| | - Jamie Schiffer
- Computational Chemistry, Therapeutics Discovery, Janssen Research & Development, LLC, 3210 Merryfield Row, La Jolla, California 92121, United States
| | - Zhicai Shi
- Discovery Chemistry, Therapeutics Discovery, Janssen Research & Development, LLC,Welsh & McKean Roads, Spring House, Pennsylvania 19477, United States
| | - Jennifer D. Venable
- Discovery Chemistry, Therapeutics Discovery, Janssen Research & Development, LLC, 3210 Merryfield Row, La Jolla, California 92121, United States
| | - Scott E. Wolkenberg
- Discovery Chemistry, Therapeutics Discovery, Janssen Research & Development, LLC,Welsh & McKean Roads, Spring House, Pennsylvania 19477, United States
| |
Collapse
|
6
|
Fu L, Zhang J, Shen B, Kong L, Liu Y, Tu W, Wang W, Cai X, Wang X, Cheng N, Xia M, Zhou T, Liu Q, Xu Y, Yang J, Gavine P, Philippar U, Attar R, Edwards JP, Venable JD, Dai X. Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL. J Med Chem 2021; 64:10878-10889. [PMID: 34279092 DOI: 10.1021/acs.jmedchem.1c00103] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
MyD88 gene mutation has been identified as one of the most prevalent driver mutations in the activated B-cell-like diffuse large B-cell lymphoma (ABC DLBCL). The published literature suggests that interleukin-1 receptor-associated kinase 1 (IRAK1) is an essential gene for ABC DLBCL harboring MyD88 mutation. Importantly, the scaffolding function of IRAK1, rather than its kinase activity, is required for tumor cell survival. Herein, we present our design, synthesis, and biological evaluation of a novel series of potent and selective IRAK1 degraders. One of the most potent compounds, Degrader-3 (JNJ-1013), effectively degraded cellular IRAK1 protein with a DC50 of 3 nM in HBL-1 cells. Furthermore, JNJ-1013 potently inhibited IRAK1 downstream signaling pathways and demonstrated strong anti-proliferative effects in ABC DLBCL cells with MyD88 mutation. This work suggests that IRAK1 degraders have the potential for treating cancers that are dependent on the IRAK1 scaffolding function.
Collapse
Affiliation(s)
- Liqiang Fu
- Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| | - Jing Zhang
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Bin Shen
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Linglong Kong
- Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| | - Yingtao Liu
- Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| | - Wangyang Tu
- Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| | - Wenqian Wang
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Xin Cai
- Department of Biomarker, Janssen Research & Development, Shanghai 201210, China
| | - Xiaotao Wang
- Department of Biomarker, Janssen Research & Development, Shanghai 201210, China
| | - Na Cheng
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Mingxuan Xia
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Tianyuan Zhou
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Qian Liu
- Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| | - Yanping Xu
- Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| | - Jennifer Yang
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Paul Gavine
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Ulrike Philippar
- Janssen Pharmaceutical Research & Development, Beerse 2340, Belgium
| | - Ricardo Attar
- Janssen Pharmaceutical Research & Development, Spring House, Pennsylvania 19477, United States
| | - James P Edwards
- Discovery Sciences, Janssen Research & Development, San Diego, California 92121, United States
| | - Jennifer D Venable
- Discovery Sciences, Janssen Research & Development, San Diego, California 92121, United States
| | - Xuedong Dai
- Discovery Sciences, Janssen (China) Research & Development, Shanghai 201210, P.R. China.,Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| |
Collapse
|
7
|
Tichenor MS, Wiener JJM, Rao NL, Pooley Deckhut C, Barbay JK, Kreutter KD, Bacani GM, Wei J, Chang L, Murrey HE, Wang W, Ahn K, Huber M, Rex E, Coe KJ, Wu J, Seierstad M, Bembenek SD, Leonard KA, Lebsack AD, Venable JD, Edwards JP. Discovery of a Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase with Oral Anti-Inflammatory Activity. ACS Med Chem Lett 2021; 12:782-790. [PMID: 34055226 DOI: 10.1021/acsmedchemlett.1c00044] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Accepted: 03/28/2021] [Indexed: 11/28/2022] Open
Abstract
Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase that plays a critical role in the activation of B cells, macrophages, and osteoclasts. Given the key role of these cell types in the pathology of autoimmune disorders, BTK inhibitors have the potential to improve treatment outcomes in multiple diseases. Herein, we report the discovery and characterization of a novel potent and selective covalent 4-oxo-4,5-dihydro-3H-1-thia-3,5,8-triazaacenaphthylene-2-carboxamide BTK inhibitor chemotype. Compound 27 irreversibly inhibits BTK by targeting a noncatalytic cysteine residue (Cys481) for covalent bond formation. Compound 27 is characterized by selectivity for BTK, potent in vivo BTK occupancy that is sustained after it is cleared from systemic circulation, and dose-dependent efficacy at reducing joint inflammation in a rat collagen-induced arthritis model.
Collapse
Affiliation(s)
- Mark S. Tichenor
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - John J. M. Wiener
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Navin L. Rao
- Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Charlotte Pooley Deckhut
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - J. Kent Barbay
- Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Kevin D. Kreutter
- Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Genesis M. Bacani
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Jianmei Wei
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Leon Chang
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Heather E. Murrey
- Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Weixue Wang
- Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Kay Ahn
- Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Michael Huber
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Elizabeth Rex
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Kevin J. Coe
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - JieJun Wu
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Mark Seierstad
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Scott D. Bembenek
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Kristi A. Leonard
- Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States
| | - Alec D. Lebsack
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - Jennifer D. Venable
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| | - James P. Edwards
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States
| |
Collapse
|
8
|
Leonard KA, Madge LA, Krawczuk PJ, Wang A, Kreutter KD, Bacani GM, Chai W, Smith RC, Tichenor MS, Harris MC, Malaviya R, Seierstad M, Johnson ME, Venable JD, Kim S, Hirst GC, Mathur AS, Rao TS, Edwards JP, Rizzolio MC, Koudriakova T. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem 2020; 63:2915-2929. [DOI: 10.1021/acs.jmedchem.9b01439] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Kristi A. Leonard
- Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Lisa A. Madge
- Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Paul J. Krawczuk
- Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Aihua Wang
- Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Kevin D. Kreutter
- Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Genesis M. Bacani
- Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States
| | - Wenying Chai
- Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States
| | - Russell C. Smith
- Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States
| | - Mark S. Tichenor
- Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States
| | - Michael C. Harris
- Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Ravi Malaviya
- Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Mark Seierstad
- Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States
| | - Marguerite E. Johnson
- Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Jennifer D. Venable
- Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States
| | - Suzie Kim
- Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States
| | - Gavin C. Hirst
- Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States
| | - Ashok S. Mathur
- Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Tadimeti S. Rao
- Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States
| | - James P. Edwards
- Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Michele C. Rizzolio
- Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States
| | - Tatiana Koudriakova
- Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States
| |
Collapse
|
9
|
Xu T, Park SK, Venable JD, Wohlschlegel JA, Diedrich JK, Cociorva D, Lu B, Liao L, Hewel J, Han X, Wong CCL, Fonslow B, Delahunty C, Gao Y, Shah H, Yates JR. ProLuCID: An improved SEQUEST-like algorithm with enhanced sensitivity and specificity. J Proteomics 2015; 129:16-24. [PMID: 26171723 DOI: 10.1016/j.jprot.2015.07.001] [Citation(s) in RCA: 335] [Impact Index Per Article: 37.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Revised: 06/08/2015] [Accepted: 07/04/2015] [Indexed: 12/25/2022]
Abstract
ProLuCID, a new algorithm for peptide identification using tandem mass spectrometry and protein sequence databases has been developed. This algorithm uses a three tier scoring scheme. First, a binomial probability is used as a preliminary scoring scheme to select candidate peptides. The binomial probability scores generated by ProLuCID minimize molecular weight bias and are independent of database size. A modified cross-correlation score is calculated for each candidate peptide identified by the binomial probability. This cross-correlation scoring function models the isotopic distributions of fragment ions of candidate peptides which ultimately results in higher sensitivity and specificity than that obtained with the SEQUEST XCorr. Finally, ProLuCID uses the distribution of XCorr values for all of the selected candidate peptides to compute a Z score for the peptide hit with the highest XCorr. The ProLuCID Z score combines the discriminative power of XCorr and DeltaCN, the standard parameters for assessing the quality of the peptide identification using SEQUEST, and displays significant improvement in specificity over ProLuCID XCorr alone. ProLuCID is also able to take advantage of high resolution MS/MS spectra leading to further improvements in specificity when compared to low resolution tandem MS data. A comparison of filtered data searched with SEQUEST and ProLuCID using the same false discovery rate as estimated by a target-decoy database strategy, shows that ProLuCID was able to identify as many as 25% more proteins than SEQUEST. ProLuCID is implemented in Java and can be easily installed on a single computer or a computer cluster. This article is part of a Special Issue entitled: Computational Proteomics.
Collapse
Affiliation(s)
- T Xu
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA; Dow AgroSciences LLC, Indianapolis, IN 46268, USA
| | - S K Park
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - J D Venable
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - J A Wohlschlegel
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - J K Diedrich
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - D Cociorva
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - B Lu
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - L Liao
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - J Hewel
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - X Han
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - C C L Wong
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - B Fonslow
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - C Delahunty
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - Y Gao
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - H Shah
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA
| | - J R Yates
- Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR11, La Jolla, CA 92037, USA.
| |
Collapse
|
10
|
Abstract
Histamine is an important endogenous signaling molecule that is involved in a number of physiological processes including allergic reactions, gastric acid secretion, neurotransmitter release, and inflammation. The biological effects of histamine are mediated by four histamine receptors with distinct functions and distribution profiles (H1-H4). The most recently discovered histamine receptor (H4) has emerged as a promising drug target for treating inflammatory diseases. A detailed understanding of the role of the H4 receptor in human disease remains elusive, in part because low sequence similarity between the human and rodent H4 receptors complicates the translation of preclinical pharmacology to humans. This review provides an overview of H4 drug discovery programs that have studied cross-species structure-activity relationships, with a focus on the functional profiling of the 2-aminopyrimidine chemotype that has advanced to the clinic for allergy, atopic dermatitis, asthma, and rheumatoid arthritis.
Collapse
Affiliation(s)
- Mark S Tichenor
- Janssen Research & Development, LLC , 3210 Merryfield Row, San Diego, California 92121, United States
| | - Robin L Thurmond
- Janssen Research & Development, LLC , 3210 Merryfield Row, San Diego, California 92121, United States
| | - Jennifer D Venable
- Janssen Research & Development, LLC , 3210 Merryfield Row, San Diego, California 92121, United States
| | - Brad M Savall
- Janssen Research & Development, LLC , 3210 Merryfield Row, San Diego, California 92121, United States
| |
Collapse
|
11
|
Venable JD, Ameriks MK, Blevitt JM, Thurmond RL, Fung-Leung WP. Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease. ACTA ACUST UNITED AC 2010; 4:1-15. [PMID: 20017720 DOI: 10.2174/187221310789895603] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2008] [Accepted: 11/21/2008] [Indexed: 11/22/2022]
Abstract
Phosphoinositide 3-kinase gamma (PI3Kgamma) is a lipid kinase in leukocytes that generates phosphatidylinositol 3,4,5-trisphosphate to recruit and activate downstream signaling molecules. Distinct from other members in the PI3K family, PI3Kgamma is activated by G-protein coupled-receptors responding to chemotactic ligands. PI3Kgamma plays an important role in migration of both myeloid and lymphoid cells. It is also required for other leukocyte functions such as neutrophil oxidative burst, T cell proliferation and mast degranulation. Mice with PI3Kgamma inactivated by genetic or pharmacological approaches are protected from disease development in a number of inflammation and autoimmune disease models. The function of PI3Kgamma depends on its kinase activity and therefore it has been suggested by many reports that small molecules inhibiting its kinase activity could be promising for the treatment of inflammation and autoimmune diseases. Over the last five years, a number of pharmaceutical companies have reported a wide variety of PI3Kgamma inhibitors, of which several x-ray crystal structures with PI3Kgamma have been elucidated. The structural characteristics and selectivity profiles of these inhibitors, in particular thiazolidinones and 2-aminoheterocycles, and those disclosed in related patent applications are summarized in this review.
Collapse
Affiliation(s)
- Jennifer D Venable
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA92121, USA.
| | | | | | | | | |
Collapse
|
12
|
Savall BM, Edwards JP, Venable JD, Buzard DJ, Thurmond R, Hack M, McGovern P. Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands. Bioorg Med Chem Lett 2010; 20:3367-71. [DOI: 10.1016/j.bmcl.2010.04.017] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2010] [Revised: 04/05/2010] [Accepted: 04/07/2010] [Indexed: 10/19/2022]
|
13
|
Venable JD, Kindrachuk DE, Peterson ML, Edwards JP. Synthesis of 3-methoxy-quinoxalin-2-ones from methyl trimethoxyacetate and phenylenediamines. Tetrahedron Lett 2010. [DOI: 10.1016/j.tetlet.2009.11.017] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
14
|
Abstract
In recent years, pharmaceutical companies have increasingly focused on phosphoinositide 3-kinases delta (PI3Kdelta) and gamma (PI3Kgamma) as therapeutic targets for the treatment of inflammatory and autoimmune diseases. All class 1 PI3-kinases (alpha/beta/gamma/delta) generate phospholipid second messengers that help govern cellular processes such as migration, proliferation, and apoptosis. PI3K delta/ gamma lipid kinases are mainly restricted to the hematopoetic system whereas PI3K alpha/beta are ubiquitously expressed, thus raising potential toxicity concerns for chronic indications such as asthma and rheumatoid arthritis. Therefore, the challenge in developing a small molecule inhibitor of PI3K is to define and attain the appropriate isoform selectivity profile. Significant advances in the design of such compounds have been achieved by utilizing x-ray crystal structures of various inhibitors bound to PI3Kgamma in conjunction with pharmacophore modeling and high-throughput screening. Herein, we review the history and challenges involved with the discovery of small molecule isoform-specific PI3K inhibitors. Recent progress in the design of selective PI3Kdelta, PI3Kgamma, and PI3Kdelta/gamma dual inhibitors will be presented.
Collapse
Affiliation(s)
- Michael K Ameriks
- Johnson & Johnson Pharmaceutical Research & Development LLC San Diego, CA 92121, USA.
| | | |
Collapse
|
15
|
Abstract
Histamine exerts its actions through four known receptors. The recently cloned histamine receptor, H4R, has been shown to have a role in chemotaxis and mediator release in various types of immune cells including mast cells, eosinophils, dendritic cells and T cells. H4R antagonists have been shown to have anti-inflammatory properties and efficacy in a number of disease models, such as those for asthma and colitis in vivo. Recently, H4R antagonists have been developed with high receptor affinity and specificity, which make them good tools for further characterisation of the receptor in animal models and, eventually, in humans. Histamine and the cells that produce it, such as mast cells and basophils, have long been thought to be involved in allergic conditions but there has recently been recognition that they may also play a role in various autoimmune diseases. Given this and the fact that the H4R has function in mast cells, dendritic cells and T cells, antagonists for the receptor may be useful in treating autoimmune diseases in addition to allergy.
Collapse
Affiliation(s)
- Mai Zhang
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA
| | | | | |
Collapse
|
16
|
Venable JD, Cai H, Chai W, Dvorak CA, Grice CA, Jablonowski JA, Shah CR, Kwok AK, Ly KS, Pio B, Wei J, Desai PJ, Jiang W, Nguyen S, Ling P, Wilson SJ, Dunford PJ, Thurmond RL, Lovenberg TW, Karlsson L, Carruthers NI, Edwards JP. Preparation and Biological Evaluation of Indole, Benzimidazole, and Thienopyrrole Piperazine Carboxamides: Potent Human Histamine H4 Antagonists. J Med Chem 2005; 48:8289-98. [PMID: 16366610 DOI: 10.1021/jm0502081] [Citation(s) in RCA: 95] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Three series of H(4) receptor ligands, derived from indoly-2-yl-(4-methyl-piperazin-1-yl)-methanones, have been synthesized and their structure-activity relationships evaluated for activity at the H(4) receptor in competitive binding and functional assays. In all cases, substitution of small lipophilic groups in the 4 and 5-positions led to increased activity in a [(3)H]histamine radiolabeled ligand competitive binding assay. In vitro metabolism and initial pharmacokinetic studies were performed on selected compounds leading to the identification of indole 8 and benzimidazole 40 as potent H(4) antagonists with the potential for further development. In addition, both 8 and 40 demonstrated efficacy in in vitro mast cell and eosinophil chemotaxis assays.
Collapse
Affiliation(s)
- Jennifer D Venable
- Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 3210 Merryfield Row, San Diego, California 92121, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Jablonowski JA, Grice CA, Chai W, Dvorak CA, Venable JD, Kwok AK, Ly KS, Wei J, Baker SM, Desai PJ, Jiang W, Wilson SJ, Thurmond RL, Karlsson L, Edwards JP, Lovenberg TW, Carruthers NI. The first potent and selective non-imidazole human histamine H4 receptor antagonists. J Med Chem 2003; 46:3957-60. [PMID: 12954048 DOI: 10.1021/jm0341047] [Citation(s) in RCA: 168] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Following the discovery of the human histamine H4 receptor, a high throughput screen of our corporate compound collection identified compound 6 as a potential lead. Investigation of the SAR resulted in the discovery of novel compounds 10e and 10l, which are the first potent and selective histamine H4 receptor antagonists to be described.
Collapse
Affiliation(s)
- Jill A Jablonowski
- Johnson & Johnson Pharmaceutical Research and Development, L.L.C, 3210 Merryfield Row, San Diego, California 92121, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|